ALZAMEND NEURO INC
ALZNNASDAQTrading Snapshot
- Day Range
- $1.42 – $1.47
- 52-Week Range
- $0.84 – $2.68
- Volume
- $2.65B
- Avg Volume
- $2.93B
- Shares Outstanding
- 3.8M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $652,241
- Last Q Revenue
- $169,733
- P/E Ratio
- -0.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.63
- Dividend Yield
- 0.00%
Why Investors Own ALZN
- ✓High-growth profile — revenue up +37.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 61% gross margin and 13% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ALZAMEND NEURO INC
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Alzamend Neuro Signs $25M Securities Purchase Agreement With Ault Lending; Alzamend Receives $7.5M In Gross Proceeds Form Initial Tranche
Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million. Catheter Precision (AMEX:VTAK)